Navigation Links
Orexigen(R) Therapeutics Appoints Peter Honig, M.D. to Board of Directors
Date:3/2/2010

scription of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward-looking statements.  These statements are based on the Company's current beliefs and expectations.  These forward-looking statements include statements regarding the potential for, and timing of, filing an NDA for Contrave.  The inclusion of forward-looking statements should not be regarded as a representation by Orexigen that any of its plans will be achieved.  Actual results may differ from those set forth in this release due to the risk and uncertainties inherent in the Orexigen business, including, without limitation: additional analyses of data from the Contrave Phase 3 trials and any other clinical trials of Contrave may produce negative or inconclusive results, or may be inconsistent with previously announced results or previously conducted clinical trials; the FDA may not agree with the Company's interpretation of efficacy and safety results; the FDA may require Orexigen to complete additional clinical, non-clinical or other requirements prior to the submission or the approval of NDA for Contrave; the third parties on whom Orexigen relies to assist with the development programs for Contrave, including clinical investigators, contract laboratories, clinical research organizations and manufacturing organizations, may not successfully carry out their contractual duties or obligations or meet expected deadlines, and the quality or accuracy of the data or materials generated by such third parties may be of insufficient quality to include in the Company's regulatory submissions; and other risks described in the Company's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date her
'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule
2. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
3. Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
4. Orexigen(R) Therapeutics Schedules July 20, 2009 Teleconference and Webcast Discussion of Contrave(R) Phase 3 Results
5. Orexigen(R) Therapeutics Schedules September 30, 2009 Teleconference and Webcast to Discuss Phase 2b Trial Results From Second Obesity Drug Candidate, Empatic(TM)
6. Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society
7. Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results
8. Orexigen(R) Therapeutics to Speak at Lazard Capital Markets Healthcare Conference
9. Orexigen(R) Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635
10. Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
11. Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... we bring you a special edition of #MedicareMonday on Medicare,s 50 th anniversary. ... Medicare resources and continue highlighting the success of the prescription drug benefit, commonly referred ... out our latest infographics and videos here: http://onphr.ma/1INp9qQ ... ... ...
(Date:7/30/2015)... Calif. , July 30, 2015  Amgen (NASDAQ: ... , partner and managing director of Warburg Pincus LLC, to ... pleased to welcome Fred Hassan and the deep, ... Amgen Board," said Robert A. Bradway , chairman and ... commitment to innovation will serve Amgen well." Mr. ...
(Date:7/30/2015)... 30, 2015 Future Market Insights ... "Continuous Glucose Monitoring Systems Market: Global Industry Analysis and ... the global continuous glucose monitoring systems market was valued ... to reach US$ 788.4 Mn by 2020, registering a ... 2020. Global continuous glucose monitoring systems market ...
Breaking Medicine Technology:Happy 50th Anniversary Medicare! 2Happy 50th Anniversary Medicare! 3Amgen Announces Appointment Of Fred Hassan To Board Of Directors 2Amgen Announces Appointment Of Fred Hassan To Board Of Directors 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 4
... Oct. 14, 2011 Pregis Corporation, a leading ... products and specialty packaging solutions, announced today that ... to sell its Kobusch-Sengewald business unit to Sun ... adviser to Sun Capital Partners, Inc., for gross ...
... ACCESS PHARMACEUTICALS, INC. ... drug-delivery platforms to develop treatments in areas of oncology, ... its MuGard website to include a clinical ... and seasoned oncology nurse practitioner,s experience with oral ...
Cached Medicine Technology:Pregis Announces Sale of Kobusch-Sengewald Business to an Affiliate of Sun European Partners 2Pregis Announces Sale of Kobusch-Sengewald Business to an Affiliate of Sun European Partners 3Access Pharmaceuticals Updates MuGard Website with New Video Featuring Clinical Feedback and Manufacturing Footage 2Access Pharmaceuticals Updates MuGard Website with New Video Featuring Clinical Feedback and Manufacturing Footage 3
(Date:8/1/2015)... ... August 01, 2015 , ... “ reTXT ” was featured on NewsWatch as ... applications on the market for iOS, Android, and Windows. Joe Toohey, the host of ... to clarify, edit and delete any message including ones already sent. , While text ...
(Date:7/31/2015)... ... , ... The Honor Society of Nursing, Sigma Theta Tau International (STTI) convened ... 20-21 July 2015 in San Juan, Puerto Rico. Key nurse leaders from Central and ... Advisor, Nursing and Allied Health Personnel Development, Unit of Human Resources for Health, Department ...
(Date:7/31/2015)... ... 2015 , ... Last week, the Mesothelioma Applied Research Foundation ... accessed by visiting http://www.curemeso.org/store . , “Our new store features a variety ... a product is purchased, the Meso Foundation receives a $5.00 donation,” said Beth ...
(Date:7/31/2015)... ... July 31, 2015 , ... Facebook, Twitter, Linkedin ... re-branded their social media profiles to better connect with the public. The agency ... find information, share insights and opinions. The Rally Insurance Group, Inc.’s pledge to ...
(Date:7/31/2015)... ... July 31, 2015 , ... According to an article ... to see if they could reach a consensus on the steps that need to ... Overall, the group reached 90 percent consensus on a series of steps that each ...
Breaking Medicine News(10 mins):Health News:Correct Auto-Correct and Clarify the Unclear with reTXT Messaging App 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 3Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 4Health News:Mesothelioma Organization Launches New Store 2Health News:Mesothelioma Organization Launches New Store 3Health News:Rally Insurance Group, Inc. Connects to Customers Through Re-branded Social Media Profiles 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 3
... JUPITER, Fla., Jan. 12 Dr. Jeffrey LaGrasso,( ... has retained TransMedia Group so that he can ... only with his elite clientele, but with,men and ... LaGrasso wants to inform consumers, for example, about ...
... AIM Pharmakon introduced next generation of ... premium quality natural liquid calcium & mineral ... market segments of athletes, women in pre ... extra calcium supplementation. The innovative products of ...
... effectiveness research tools to address large, unwarranted variations in project ... spending. , ... Phoenixville, Pennsylvania (PRWEB) ... addresses large and unwarranted variations in corporate spending. As an ...
... Calif., Jan. 12 Acclarent, Inc., a leading,medical ... that address conditions affecting the ear, nose and,throat, ... dollar financing round.,Acclarent intends to use the proceeds ... well as on-going investment in product,development and clinical ...
... effective, but must be used with caution, experts say ... anticoagulant -- or "blood thinner" -- that,s frequently prescribed ... million Americans have the cardiac condition, which causes the ... efficiently. This leaves people vulnerable to a blood clot ...
... and manufacturing of cell culture media and cell separation products for ... new sales and distribution office in Singapore, effective January 12th, 2009. ... ... -- STEMCELL Technologies Inc (STEMCELL), a leader in the ...
Cached Medicine News:Health News:TransMedia Group Retained by Renowned Plastic Surgeon Dr. Jeffrey Lagrasso to Share Beauty Trends, Warnings and Medical Perspective Previously Limited to the Rich and Famous 2Health News:AIM Pharmakon Introduced Next Generation of Health and Longevity Products with a Unique Premium Quality Natural Liquid Calcium & Mineral Supplement Concentrate 2Health News:AIM Pharmakon Introduced Next Generation of Health and Longevity Products with a Unique Premium Quality Natural Liquid Calcium & Mineral Supplement Concentrate 3Health News:AIM Pharmakon Introduced Next Generation of Health and Longevity Products with a Unique Premium Quality Natural Liquid Calcium & Mineral Supplement Concentrate 4Health News:Comparative Effectiveness Research Tools Address Variations in corporate spending 2Health News:Comparative Effectiveness Research Tools Address Variations in corporate spending 3Health News:Acclarent, Inc. Closes $26 Million Financing 2Health News:Doctors Re-Examine Blood Thinners to Prevent Strokes 2Health News:STEMCELL Technologies Launches Direct Distribution to Singapore 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: